MIST
HEALTHCAREMilestone Pharmaceuticals Inc
$1.97+0.09 (+4.79%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving MIST Today?
No stock-specific AI insight has been generated for MIST yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.00$3.06
$1.97
Fundamentals
Market Cap$226M
P/E Ratio—
EPS$-0.75
Dividend Yield—
Dividend / Share—
ROE-2.3%
Profit Margin—
Debt / Equity—
Trading
Volume1.4M
Avg Volume (10D)—
Shares Outstanding119.6M
MIST News
20 articles- Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026Yahoo Finance·May 6, 2026
- Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVTGlobeNewswire Inc.·Apr 10, 2026
- Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 7, 2026
- Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 2, 2026
- Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National FormulariesYahoo Finance·Mar 31, 2026
- Milestone Pharmaceuticals Inc (MIST) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ...Yahoo Finance·Mar 20, 2026
- Milestone Pharmaceuticals Q4 Earnings Call HighlightsMarketbeat·Mar 20, 2026
- Milestone Pharmaceuticals: Q4 Earnings SnapshotYahoo Finance·Mar 20, 2026
- Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVTYahoo Finance·Mar 20, 2026
- Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific SessionYahoo Finance·Mar 16, 2026
- Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026Yahoo Finance·Mar 12, 2026
- Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care ConferenceYahoo Finance·Feb 26, 2026
- Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance OfficerYahoo Finance·Feb 10, 2026
- All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong BuyYahoo Finance·Jan 27, 2026
- Milestone Pharmaceuticals announces U.S. availability of cardamystYahoo Finance·Jan 27, 2026
- Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)Yahoo Finance·Jan 26, 2026
- Milestone announces acceptance of MAA by EMA for etripamil nasal sprayYahoo Finance·Jan 7, 2026
- Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines AgencyYahoo Finance·Jan 6, 2026
- Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)Yahoo Finance·Dec 17, 2025
- Milestone Pharmaceuticals upgraded to Buy at TD Cowen after Cardamyst approvalYahoo Finance·Dec 16, 2025
All 20 articles loaded
Price Data
Open$1.91
Previous Close$1.88
Day High$1.94
Day Low$1.88
52 Week High$3.06
52 Week Low$1.00
52-Week Range
$1.00$3.06
$1.97
Fundamentals
Market Cap$226M
P/E Ratio—
EPS$-0.75
Dividend Yield—
Dividend / Share—
ROE-2.3%
Profit Margin—
Debt / Equity—
Trading
Volume1.4M
Avg Volume (10D)—
Shares Outstanding119.6M
About Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular drugs. The company is headquartered in Montral, Canada.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—